The design of CARs with the ability to upregulate chemokine receptors might also facilitate T cell trafficking and increase T cell fitness and survival of CAR T cells in a composite T cell therapy approach with the aim to increase MHC expression on tumor cells and to downregulate immune suppressive factors elaborated by non-transformed cells–or by tumor-associated pathogens–in the TME. This evidence concerns the gene HLA-C and neoplasm.